Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

  • Technology appraisal guidance
  • TA377
  • Published: 
Download (PDF)

Why has NICE said this?

NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.

Enzalutamide was recommended because the benefits to patients justify its cost.

  • Information Standard